Literature DB >> 202693

Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.

R J Laffan, M E Goldberg, J P High, T R Schaeffer, M H Waugh, B Rubin.   

Abstract

SQ 14,225 (D-3-mercapto-2-methylpropanoyl-L-proline) markedly lowered the blood pressure of the renin-dependent aortic-ligated and two-kidney Goldblatt hypertensive rat and failed to reduce blood pressure in the one-kidney Goldblatt hypertensive rat. In the two-kidney Goldblatt rat, SQ 14,225 (p.o.) was about 10 times as potent as teprotide, the nonapeptide SQ 20,881 (s.c.). Oral doses of SQ 14,225 moderately reduced the blood pressure of the Wistar-Kyoto spontaneously hypertensive rat but not that of the normotensive Wistar-Kyoto rat. Bilateral nephrectomy abolished the antihypertensive activity of SQ 14,225 in the spontaneously hypertensive rat. SQ 14,225 and SQ 20,881 elicited parallel dose-response curves in the two-kidney renal hypertensive rat. Post-treatment of spontaneously hypertensive rats with either agent failed to augment the antihypertensive effect produced by effective doses of the other agent. The results suggest that SQ 14,225 acts primarily by inhibiting the renin-angiotensin system to reduce elevated blood pressure, especially in presumably renin-dependent models of hypertension.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 202693

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Mass spectral fragmentation reactions of angiotensin-converting enzyme (ACE) inhibitors.

Authors:  David J Burinsky; Scott L Sides
Journal:  J Am Soc Mass Spectrom       Date:  2004-09       Impact factor: 3.109

2.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets.

Authors:  Zhi Chen; Hong-lin Li; Qi-jun Zhang; Xiao-guang Bao; Kun-qian Yu; Xiao-min Luo; Wei-liang Zhu; Hua-liang Jiang
Journal:  Acta Pharmacol Sin       Date:  2009-11-23       Impact factor: 6.150

Review 4.  Preclinical studies on angiotensin converting enzyme inhibitors.

Authors:  I L Natoff
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 5.  How ACE inhibitors transformed the renin-angiotensin system.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

6.  Inhibition of vascular permeability changes in rats by captopril.

Authors:  J C Fantone; D Schrier; B Weingarten
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

7.  A clinician looks at the future.

Authors:  C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

8.  The effect of SQ 14225 on fluid intake in DOCA/salt hypertensive rats [proceedings].

Authors:  H G Dean; S Ingham
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

9.  Alterations in responses to bradykinin, angiotensin I, and angiotensin II during the induction phase of one-kidney, one-wrapped hypertension and associated arterial disease in rabbits.

Authors:  W G Campbell; J A Donohue; L H Duket
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

10.  Effects of captopril on left ventricular structure and function in SHR with established hypertension.

Authors:  C A Canby; P J Palmer; K R Wall; R J Tomanek
Journal:  Basic Res Cardiol       Date:  1989 May-Jun       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.